{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:49:03Z","timestamp":1790732943964,"version":"4.1.0"},"reference-count":47,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["FAPESP 2018\/05616\u20103"],"award-info":[{"award-number":["FAPESP 2018\/05616\u20103"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["303142\/2019\u2010"],"award-info":[{"award-number":["303142\/2019\u2010"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["7165620\/2018\u20108"],"award-info":[{"award-number":["7165620\/2018\u20108"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>\n                    The activity of the membrane transporters organic anion\u2010transporting polypeptide 1B1 (OATP1B1) &amp; breast cancer resistance protein (BCRP) (rosuvastatin) and P\u2010glycoprotein (P\u2010gp) (fexofenadine) was evaluated in patients with chronic hepatitis C virus (HCV) infection (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200928), genotypes 1 and 3, investigated before the treatment with direct\u2010acting antiviral agents (Phase 1) and up to 30\u2009days after the assessment of the virologic response (Phase 2). Participants allocated in Groups 1 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200915; F0\/F1 and F2, mild to moderate liver fibrosis) and 2 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200913; F3 and F4, advanced course of liver fibrosis\/cirrhosis) received in both phases fexofenadine (10\u2009mg) and rosuvastatin (2\u2009mg). OATP1B1 &amp; BCRP activity (rosuvastatin area under the plasma concentration\u2010time curve of rosuvastatin from time zero to infinity (AUC\n                    <jats:sub>0\u2013\u221e<\/jats:sub>\n                    )) was reduced in Groups 1 and 2, respectively, by 25% (ratio 0.75 (0.53\u20130.82),\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01) and 31% (ratio 0.69 (0.46\u20130.85),\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05) in Phase 1 compared with Phase 2. OATP1B1 &amp; BCRP activity was reduced in Phases 1 and 2, respectively, by 49% (median ratio 1.51 (1.17\u20132.20),\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05) and 61% (ratio 1.39 (1.16\u20132.02),\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01) in Group 2 compared with Group 1. P\u2010gp activity (fexofenadine AUC\n                    <jats:sub>0\u2013\u221e<\/jats:sub>\n                    ) was also reduced in Phase 1 compared with Phase 2 (ratio Phase2\/Phase1 0.79 (0.66\u20130.96) in Group 1 and 0.81 (0.69\u20130.96) in Group 2) as well as in Group 2 compared with Group 1 in both Phases (ratio Group2\/Group1 1.47 (1.08\u20132.01) in Phase 1 and 1.51 (1.10\u20132.07) in Phase 2). Thus, clinicians administering OATP1B1 &amp; BCRP and P\u2010gp substrates with low therapeutic indexes should consider the evolution of the treatment and the stage of HCV infection.\n                  <\/jats:p>","DOI":"10.1002\/cpt.2908","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T09:44:03Z","timestamp":1681811043000},"page":"173-181","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of Chronic Hepatitis C on the Activity of the Membrane Transporters P\u2010gp and OATP1B1\/BCRP on Patients With Different Stages of Hepatic Fibrosis"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2782-0389","authenticated-orcid":false,"given":"Leandro Francisco","family":"Pippa","sequence":"first","affiliation":[{"name":"Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9134-0315","authenticated-orcid":false,"given":"Carolina Pinto","family":"Vieira","sequence":"additional","affiliation":[{"name":"Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-2836","authenticated-orcid":false,"given":"Juciene Aparecida","family":"Caris","sequence":"additional","affiliation":[{"name":"Department of Neurosciences and Behavioral Sciences, School of Medicine of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rocha","sequence":"additional","affiliation":[{"name":"Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Paula","family":"Marques","sequence":"additional","affiliation":[{"name":"Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camile Prates","family":"Garcia","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, School of Medicine of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3895-0864","authenticated-orcid":false,"given":"Rosamar Eulira Fontes","family":"Rezende","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, School of Medicine of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto S\u00e3o Paulo Brazil"},{"name":"Reference Center, Hepatitis Outpatient Clinic Municipal Health Secretary  Ribeir\u00e3o Preto S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0074-4953","authenticated-orcid":false,"given":"Vera Lucia","family":"Lanchote","sequence":"additional","affiliation":[{"name":"Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"e_1_2_9_1_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.733935"},{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1093"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425250903304056"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.023630"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105264"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12808"},{"key":"e_1_2_9_7_1","unstructured":"HepatitisC.Hepatitis C <https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/hepatitis\u2010c>."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-11-RG-077"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.020073"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2014.08.198"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.10.006"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219508"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12028"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00216-1"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.placenta.2018.07.005"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.25.190"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.071050"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1379"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1717"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147947"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1916"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/03639045.2015.1096278"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.525"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0508-8"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408347.2018.1439364"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14829"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.11.018"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240201"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-123576"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00022"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.113"},{"key":"e_1_2_9_32_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2022"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32834300cc"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.01.018"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.08.026"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.017814"},{"key":"e_1_2_9_38_1","first-page":"866","article-title":"OATP and P\u2010glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine","volume":"27","author":"Cvetkovic M.","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.004192"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.163"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.062174"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.736"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100220"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1216"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.12"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1098"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15485"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:37:59Z","timestamp":1699346279000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/cpt.2908"],"URL":"https:\/\/doi.org\/10.1002\/cpt.2908","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"2022-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}